Literature DB >> 12920256

Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases.

Timo E Strandberg1, Kaisu H Pitkala, Kimmo H Linnavuori, Reijo S Tilvis.   

Abstract

BACKGROUND AND
PURPOSE: Inflammation and infectious etiology have been implicated in the pathogenesis of dementia. We sought to investigate whether the seropositivity of common infections was associated with cognitive function.
METHODS: Viral burden (seropositivity for herpes simplex virus type 1 [HSV-1], herpes simplex virus type 2 [HSV-2], or cytomegalovirus [CMV]) and bacterial burden (Chlamydia pneumoniae and Mycoplasma pneumoniae) were related to cognitive status and its impairment among 383 home-dwelling elderly with cardiovascular diseases (mean age, 80 years). The Mini-Mental State Examination (MMSE) and its changes and the Clinical Dementia Rating (CDR) were used to define cognitive impairment.
RESULTS: At baseline, 0 to 1, 2, and 3 positive titers toward viruses were found in 48 (12.5%), 229 (59.8%), and 106 individuals (27.7%), respectively. MMSE points decreased with increasing viral burden (P=0.03). At baseline, 58 individuals (15.1%) had cognitive impairment, which after adjustments was significantly associated with seropositivity for 3 viruses (hazard ratio, 2.5; 95% CI, 1.3 to 4.7). MMSE score decreased in 150 (43% of 348) during 12-month follow-up. After adjustment for MMSE score at baseline and with 0 to 1 seropositivities as reference (1.0), the hazard ratios were 1.8 (95% CI, 0.9 to 3.6) and 2.3 (95% CI, 1.1 to 5.0) for 2 and 3 seropositivities, respectively. The prevalence of possible or definite dementia according to CDR also increased with viral burden. No significant associations were observed between bacterial burden and cognition.
CONCLUSIONS: Viral pathogen burden of HSV and CMV was associated with cognitive impairment in home-dwelling elderly persons with cardiovascular diseases. The results need to be tested in larger databases, but they may offer a preventable cause of cognitive decline.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920256     DOI: 10.1161/01.STR.0000086754.32238.DA

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  47 in total

1.  Antiviral agents in Alzheimer's disease: hope for the future?

Authors:  Matthew A Wozniak; Ruth F Itzhaki
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

2.  Temporal Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based, Aging Cohort.

Authors:  Vishwajit L Nimgaonkar; Robert H Yolken; Tianxiu Wang; Chung-Chou H Chang; Lora McClain; Eric McDade; Beth E Snitz; Mary Ganguli
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jul-Sep       Impact factor: 2.703

3.  Carotid atherosclerosis, cytomegalovirus infection, and cognitive decline in the very old: a community-based prospective cohort study.

Authors:  Midori Kawasaki; Yasumichi Arai; Michiyo Takayama; Takumi Hirata; Midori Takayama; Yukiko Abe; Hidehito Niimura; Masaru Mimura; Toru Takebayashi; Nobuyoshi Hirose
Journal:  Age (Dordr)       Date:  2016-02-17

Review 4.  Inflammation and ageing.

Authors:  U Müller-Werdan
Journal:  Z Gerontol Geriatr       Date:  2007-10       Impact factor: 1.281

5.  When is critical illness not like an asteroid strike?

Authors:  Theodore J Iwashyna; Hallie C Prescott
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

6.  An ELISA method to compute endpoint titers to Epstein-Barr virus and cytomegalovirus: application to population-based studies.

Authors:  Raymond P Stowe; R Jeanne Ruiz; Christopher P Fagundes; Robin H Stowe; Min Chen; Ronald Glaser
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

7.  Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia.

Authors:  Brian H Shirts; Konasale M Prasad; Michael F Pogue-Geile; Faith Dickerson; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2008-09-17       Impact factor: 4.939

8.  Reply to Itzhaki.

Authors:  Lisa L Barnes; Ana W Capuano; Allison E Aiello; Arlener D Turner; Robert H Yolken; E Fuller Torrey; David A Bennett
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

9.  Infectious burden and cognitive function: the Northern Manhattan Study.

Authors:  Mira Katan; Yeseon Park Moon; Myunghee Cho Paik; Ralph L Sacco; Clinton B Wright; Mitchell S V Elkind
Journal:  Neurology       Date:  2013-03-26       Impact factor: 9.910

10.  Infectious Burden and Cognitive Decline in the Northern Manhattan Study.

Authors:  Clinton B Wright; Hannah Gardener; Chuanhui Dong; Mitsuhiro Yoshita; Charles DeCarli; Ralph L Sacco; Yaakov Stern; Mitchell S V Elkind
Journal:  J Am Geriatr Soc       Date:  2015-08       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.